Imaging in metastatic renal cell carcinoma

American Journal of Roentgenology

Volumn 189, Issue 2, 2007, Pages 360-370

  Griffin, Nyree ^a   Gore, Martin E ^a   Sohaib, S Aslam ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

CT; Kidney; Renal cell carcinoma

Indexed keywords

ADVANCED CANCER; BONE METASTASIS; BRAIN METASTASIS; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MEDIASTINUM METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; THORAX RADIOGRAPHY; TISSUE DISTRIBUTION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CONTRAST MEDIA; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547609266     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2077     Document Type: Review

References (75)

1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Available at: http://www.cochrane.org/reviews/ en/ab001425.html. Accesssed May 24, 2007
2. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524
3. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512
4. Gore ME, Escudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 2006; 20[6 suppl 5]:19-24
5. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970
6. Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005; 95:522-525
7. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 2005; 3:48
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130
9. Sivaramakrishna B, Gupta NP, Wadhwa P, et al. Pattern of metastases in renal cell carcinoma: a single institution study. Indian J Cancer 2005; 42:173-177
10. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30:843-852
11. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154:28-31
12. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982; 20:177-181
13. Davis SD, Koizumi JH, Pitts WR. Spontaneous regression of pulmonary metastases from renal cell carcinoma. Urology 1989; 33:141-144
14. Masatoshi M, Masatsugu I, Jun-ichiro I, Shiro B. An optimal follow-up protocol for renal cell carcinoma based on the occurrence of recurrences after surgery [in Japanese]. Nippon Hinyokika Gakkai Zasshi 2000; 91:700-707
15. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997; 157:2067-2070
16. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage-specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163-1167
17. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4:385-390
18. O'Dea MJ, Zincke H, Utz DC, Bernatz PE. The treatment of renal cell carcinoma with solitary metastasis. J Urol 1978; 120:540-542
19. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-663
20. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095; quiz 1295
21. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61:314-319
22. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659
23. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995-3002
24. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-133
25. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11:71-77
26. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26:281-291
27. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. Am J Clin Pathol 1999; 111:539-543
28. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540
29. Bruno JJ 2nd, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 2006; 97:933-938
30. Saidi JA, Newhouse JH, Sawczuk IS. Radiologic follow-up of patients with T1-3a,b,c or T4N+M0 renal cell carcinoma after radical nephrectomy. Urology 1998; 52:1000-1003
31. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994; 12:206-212
32. Cozzoli A, Milano S, Cancarini G, Zanotelli T, Cosciani Cunico S. Surgery of lung metastases in renal cell carcinoma. Br J Urol 1995; 75:445-447
33. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000; 164:1505-1508
34. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983; 10:390-400
35. Kuczyk MA, Bokemeyer C, Kohn G, et al. Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br J Urol 1997; 80:18-24
36. Stenzl A, deKernion JB. The natural history of renal cell carcinoma. Semin Urol 1989; 7:144-148
37. Beisland C, Medby PC, Beisland HO. Presumed radically treated renal cell carcinoma: recurrence of the disease and prognostic factors for subsequent survival. Scand J Urol Nephrol 2004; 38:299-305
38. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24:3101-3106
39. Chae EJ, Kim JK, Kim SH, Bae SJ, Cho KS. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 2005; 234:189-196
40. Dinney CP, Awad SA, Gajewski JB, et al. Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology 1992; 39:122-129
41. Park YW, Hlivko TJ. Parotid gland metastasis from renal cell carcinoma. Laryngoscope 2002; 112:453-456
42. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993; 150:1112-1114
43. 18F-fluoro-2-deoxyglucose positron emission tomography: a preliminary report. Urol Int 2003; 71:306-309
44. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171:1806-1809
45. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21:3995-4000
46. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60:395-400
47. Safaei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for restaging of renal cell cancer. Clin Nephrol 2002; 57:56-62
48. Alter AJ, Uehling DT, Zwiebel WJ. Computed tomography of the retroperitoneum following nephrectomy. Radiology 1979; 133:663-668
49. Tartar VM, Heiken JP, McClennan BL. Renal cell carcinoma presenting with diffuse peritoneal metastases: CT findings. J Comput Assist Tomogr 1991; 15:450-453
50. Roviello F, Caruso S, Moscovita Falzarano S, et al. Small bowel metastases from renal cell carcinoma: a rare cause of intestinal intussusception. J Nephrol 2006; 19:234-238
51. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322-325
52. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825-830
53. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol 1994; 152:1082-1085
54. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. RadioGraphics 2001; 21[spec no]:S237-S254
55. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-2821
56. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996; 35:146-150
57. Levine E. Renal cell carcinoma: clinical aspects, imaging diagnosis, and staging. Semin Roentgenol 1995; 30:128-148
58. Henriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 1992; 26:363-366
59. Staudenherz A, Steiner B, Puig S, Kainberger F, Leitha T. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 1999; 85:153-155
60. Hughes MJ, Sohaib SA, Eisen T, Gore M. Comparison of whole-body MR imaging and bone scintigraphy in the detection of bone metastases in renal carcinoma. AJR 2005; 184 [American Roentgen Ray Society 105th Annual Meeting Abstract Book suppl]:31
61. 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 1997; 169:1655-1661
62. 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 2002; 128:503-506
63. Seto E, Segall GM, Terris MK. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 2000; 55:286
64. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared with CCT in patients with brain metastases. J Neurooncol 1999; 44:275-281
65. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005; 6:7-18
66. Miller AB. Reporting results of cancer treatment. Cancer 1981; 47:207-214
67. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
68. Negrier S, Thiesse C, Vincent C, et al. Different measurement criteria give different tumour response classifications in patients with metastatic renal cell cancer (MRCC). (abstr 6013) Proc Am Soc Clin Oncol 2004 2004; 23:520
69. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000; 73:1178-1184
70. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42:1031-1039
71. Schwartz LH, Mazumdar M, Wang L, et al. Response assessment classification inpatients with advanced renal cell carcinoma treated on clinical trials. Cancer 2003; 98:1611-1619
72. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14:123-130
73. Rosen M, Veronese M, Lee R, et al. Dynamic contrast-enhanced MRI (DCE-MRI) of primary and metastatic renal cell carcinoma in humans: measurement of tumor vascularity as a means of assessing anti-vascular effects of BAY-43-9006 in vivo. (abstr) Radiological Society of North America 90th scientific assembly and annual meeting program. 2004:155
74. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42:2472-2479
75. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 2004; 183:1619-1628